Share this article
Share this article
SHANGHAI, July 8, 2021 /PRNewswire/ BioShin Limited today announced the appointment of Dr. Zhihong (Sarah) Lu as Chief Medical Officer and Dr. Ma (Mary) Li as Chief Commercial Officer. Sarah will play a critical role in BioShin s clinical development of pipeline products in Asia-Pacific markets, while Mary will be responsible for BioShin s commercial operations, including product strategy, access, sales, marketing and distribution. Both will report to Dr. Karl Lintel, CEO of BioShin. Bringing extensive management experience and deep expertise, they will greatly strengthen and complement BioShin s senior leadership team. We are honored to have Sarah and Mary join the BioShin team, said Karl Lintel. As an innovative biopharmaceutical company focusing on neuroscience, we are committed to the discovery, development and marketing of world leading novel life-improving treatments for patients with neurological diseases in Asia-Pacific countrie